Valneva SE Sponsored ADR (NASDAQ:VALN) Sees Large Increase in Short Interest

Valneva SE Sponsored ADR (NASDAQ:VALN) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 173,642 shares, an increase of 25.4% from the February 26th total of 138,488 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 13,666 shares, the short-interest ratio is presently 12.7 days.

Institutional Investors Weigh In On Valneva

A number of institutional investors and hedge funds have recently modified their holdings of VALN. Frazier Life Sciences Management L.P. purchased a new position in Valneva in the 2nd quarter valued at approximately $8,240,000. Marex Group plc acquired a new stake in Valneva in the second quarter valued at $64,000. XTX Topco Ltd acquired a new stake in Valneva in the fourth quarter valued at $94,000. JPMorgan Chase & Co. purchased a new position in shares of Valneva in the third quarter valued at $124,000. Finally, VSM Wealth Advisory LLC increased its position in shares of Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Stock Performance

NASDAQ:VALN opened at $6.25 on Wednesday. The firm’s fifty day simple moving average is $9.78 and its 200-day simple moving average is $9.57. The company has a quick ratio of 1.85, a current ratio of 2.38 and a debt-to-equity ratio of 1.52. The stock has a market cap of $538.19 million, a PE ratio of -3.96 and a beta of 1.80. Valneva has a fifty-two week low of $5.43 and a fifty-two week high of $12.25.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.68) EPS for the quarter. The company had revenue of $55.92 million during the quarter. Valneva had a negative net margin of 67.64% and a negative return on equity of 76.81%. Analysts expect that Valneva will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.00.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.